18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Breast Cancer, Lung Cancer, Colorectal Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/7/2018 |
| Start Date: | March 2013 |
| End Date: | March 2019 |
Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer
patients. We will assess the uptake of this novel radiopharmaceutical in subjects with breast
cancer, lung cancer, glioblastoma multiforme (GBM) and other cancers requiring
antiangiogenesis treatment.
patients. We will assess the uptake of this novel radiopharmaceutical in subjects with breast
cancer, lung cancer, glioblastoma multiforme (GBM) and other cancers requiring
antiangiogenesis treatment.
PRIMARY OBJECTIVES:
I. Evaluate 18F FPPRGD2 PET/CT or PET/MRI for prediction and early assessment of response to
anti-angiogenesis therapy in patients with non-small cell lung cancer (NSCLC), breast cancer,
glioblastoma multiforme (GBM) and other cancers.
OUTLINE:
Patients undergo 18F FPPRGD2 PET/CT or PET/MRI at baseline, 1 week, and 6 weeks (or standard
of care follow-up) and 18F FDG PET/CT at baseline and 6 weeks (or standard of care follow-up)
.
After completion of study imaging, patients are followed up at 12 months.
I. Evaluate 18F FPPRGD2 PET/CT or PET/MRI for prediction and early assessment of response to
anti-angiogenesis therapy in patients with non-small cell lung cancer (NSCLC), breast cancer,
glioblastoma multiforme (GBM) and other cancers.
OUTLINE:
Patients undergo 18F FPPRGD2 PET/CT or PET/MRI at baseline, 1 week, and 6 weeks (or standard
of care follow-up) and 18F FDG PET/CT at baseline and 6 weeks (or standard of care follow-up)
.
After completion of study imaging, patients are followed up at 12 months.
Inclusion Criteria:
- Provides written informed consent
- Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and
neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis
treatment
- Able to remain still for duration of each imaging procedure (about one hour)
Exclusion Criteria:
- Pregnant or nursing
We found this trial at
1
site
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials
